• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
An Update on Prevention of Paediatric Respiratory Syncytial Virus Hospitalizations in Canada.加拿大预防小儿呼吸道合胞病毒住院治疗的最新情况
J Assoc Med Microbiol Infect Dis Can. 2025 Mar 26;10(1):2-5. doi: 10.3138/jammi-2025-0203. eCollection 2025 Mar.
2
Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment.意大利婴儿中使用呼吸道合胞病毒前体融合蛋白（RSVpreF）疫苗和单克隆抗体进行母体免疫预防呼吸道合胞病毒的补充策略：成本效益评估
Infect Dis Ther. 2025 Jul 18. doi: 10.1007/s40121-025-01193-4.
3
Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner.儿童呼吸道合胞病毒免疫：过去、现在与即将到来的未来。
Hum Vaccin Immunother. 2025 Dec;21(1):2521920. doi: 10.1080/21645515.2025.2521920. Epub 2025 Jun 24.
4
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.孕期接种呼吸道合胞病毒疫苗以改善婴儿结局。
Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2.
5
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.呼吸道合胞病毒疾病负担及尼塞韦单抗预防和保护婴儿疾病效用的专家共识。
World J Pediatr. 2025 Jun 28. doi: 10.1007/s12519-025-00926-2.
6
Evaluation of pregnant women's knowledge about RSV and immunization attitudes before infant immunization with monoclonal antibodies in Turkey.土耳其在婴儿使用单克隆抗体免疫接种前对孕妇关于呼吸道合胞病毒（RSV）的知识及免疫态度的评估。
J Trop Pediatr. 2025 Jun 7;71(4). doi: 10.1093/tropej/fmaf024.
7
Approach to prevention of respiratory syncytial virus disease in infants by passive immunization.通过被动免疫预防婴儿呼吸道合胞病毒疾病的方法。
Can Fam Physician. 2024 Nov-Dec;70(11-12):697-700. doi: 10.46747/cfp.701112697.
8
The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy.尼塞韦单抗预防对呼吸道合胞病毒住院治疗的影响：意大利托斯卡纳的一项真实世界成本效益分析
Front Public Health. 2025 Jul 3;13:1604331. doi: 10.3389/fpubh.2025.1604331. eCollection 2025.
9
Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus.使用呼吸道合胞病毒融合前体蛋白（RSVpreF）对迪拜的私人保险婴儿进行母体疫苗接种以预防呼吸道合胞病毒的预算影响。
Hum Vaccin Immunother. 2025 Dec;21(1):2523106. doi: 10.1080/21645515.2025.2523106. Epub 2025 Jul 2.
10
Maternal RSVpreF Vaccine: A Novel Agent for Respiratory Syncytial Virus Prevention in Infants.母体呼吸道合胞病毒前融合蛋白疫苗：预防婴儿呼吸道合胞病毒的新型制剂。
Ann Pharmacother. 2025 Aug;59(8):758-766. doi: 10.1177/10600280241302775. Epub 2024 Dec 30.

本文引用的文献

1
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine.来自二价呼吸道合胞病毒预融合F蛋白疫苗的MATISSE（安全性和有效性的母体免疫研究）母体试验的早产频率及相关结局
Obstet Gynecol. 2025 Feb 1;145(2):147-156. doi: 10.1097/AOG.0000000000005817. Epub 2025 Jan 2.
2
FDA pauses all infant RSV vaccine trials after rise in severe illnesses.在严重疾病病例增加后，美国食品药品监督管理局暂停了所有婴儿呼吸道合胞病毒疫苗试验。
BMJ. 2024 Dec 23;387:q2852. doi: 10.1136/bmj.q2852.
3
Full 2023-24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study.西班牙加利西亚地区使用尼塞韦单抗进行普遍预防的2023 - 2024年完整赛季结果：NIRSE - GAL研究
Lancet Infect Dis. 2025 Feb;25(2):e62-e63. doi: 10.1016/S1473-3099(24)00811-9. Epub 2024 Dec 12.
4
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.2023 - 2024年呼吸道合胞病毒疾病负担及尼塞韦单抗在幼儿中的有效性
JAMA Pediatr. 2025 Feb 1;179(2):179-187. doi: 10.1001/jamapediatrics.2024.5572.
5
Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis.尼塞韦单抗——呼吸道合胞病毒细支气管炎的一项突破。
Lancet Child Adolesc Health. 2024 Oct;8(10):708-709. doi: 10.1016/S2352-4642(24)00228-1. Epub 2024 Aug 26.
6
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.加拿大婴儿呼吸道合胞病毒疾病预防用 RSVpreF 疫苗和 nirsevimab 的成本效益分析。
Vaccine. 2024 Aug 30;42(21):126164. doi: 10.1016/j.vaccine.2024.126164. Epub 2024 Jul 30.
7
Nirsevimab and Hospitalization for RSV Bronchiolitis.尼赛珠单抗与 RSV 毛细支气管炎住院治疗。
N Engl J Med. 2024 Jul 11;391(2):144-154. doi: 10.1056/NEJMoa2314885.
8
Burden of disease of respiratory syncytial virus in infants, young children and pregnant women and people.呼吸道合胞病毒在婴幼儿、孕妇及人群中的疾病负担
Can Commun Dis Rep. 2024 Jan 1;50(1-2):1-15. doi: 10.14745/ccdr.v50i12a01.
9
The rapidly changing landscape of respiratory syncytial virus prophylaxis.呼吸道合胞病毒预防领域迅速变化的局面。
J Assoc Med Microbiol Infect Dis Can. 2023 Nov 29;8(3):165-171. doi: 10.3138/jammi-2023-05-31. eCollection 2023 Nov.
10
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.儿科呼吸道合胞病毒相关住院治疗在 COVID-19 大流行之前和期间。
JAMA Netw Open. 2023 Oct 2;6(10):e2336863. doi: 10.1001/jamanetworkopen.2023.36863.

An Update on Prevention of Paediatric Respiratory Syncytial Virus Hospitalizations in Canada.

作者信息

Robinson Joan L, Papenburg Jesse

机构信息

Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.

Department of Pediatrics, McGill University, Montreal, Quebec, Canada.

出版信息

J Assoc Med Microbiol Infect Dis Can. 2025 Mar 26;10(1):2-5. doi: 10.3138/jammi-2025-0203. eCollection 2025 Mar.

DOI:10.3138/jammi-2025-0203
PMID:40671849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12258633/
Abstract
摘要